Stramer Susan L, Fang Chyang T, Foster Gregory A, Wagner Annette G, Brodsky Jaye P, Dodd Roger Y
American Red Cross, Gaithersburg, Md 20877, USA.
N Engl J Med. 2005 Aug 4;353(5):451-9. doi: 10.1056/NEJMoa044333.
West Nile virus first appeared in the United States in 1999 and has since spread throughout the contiguous states, resulting in thousands of cases of disease. By 2002, it was clear that the virus could be transmitted by blood transfusion, and by the middle of 2003, essentially all blood donations were being tested for West Nile virus RNA with the use of investigational nucleic acid amplification tests; testing was performed on individual samples or on "minipools" of up to 16 donations.
We analyzed data from the West Nile virus testing program of the American Red Cross for 2003 and 2004 to identify geographic and temporal trends. In areas with a high incidence of infection, individual donations were tested to increase the sensitivity of testing. Donors with reactive results participated in follow-up studies to confirm the original reactivity and to assess the natural history of infection.
Routine testing in 2003 and 2004 identified 540 donations that were positive for West Nile virus RNA, of which 362 (67 percent) were IgM-antibody-negative and most likely infectious. Of the 540 positive donations, 148 (27 percent) were detectable only by testing of individual donations, but only 15 of the 148 (10 percent) were negative for IgM antibody. The overall frequencies of RNA-positive donations during the epidemic periods were 1.49 per 10,000 donations in 2003 and 0.44 per 10,000 in 2004. In 2004, 52 percent of the positive donations were from donors in four counties in southern California.
Rapid implementation of a nucleic acid amplification test led to the prospective identification of 519 donors who were positive for West Nile virus RNA and the removal of more than 1000 potentially infectious related components from the blood supply of the Red Cross. No cases of transfusion-transmitted infection were confirmed among recipients of the tested blood.
西尼罗河病毒于1999年首次在美国出现,此后已蔓延至美国本土各州,导致数千例疾病发生。到2002年,很明显该病毒可通过输血传播,到2003年年中,基本上所有献血都在使用试验性核酸扩增检测法检测西尼罗河病毒RNA;检测是对单个样本或多达16份献血的“微池”进行的。
我们分析了美国红十字会2003年和2004年西尼罗河病毒检测项目的数据,以确定地理和时间趋势。在感染发生率高的地区,对单个献血进行检测以提高检测的敏感性。检测结果呈阳性的献血者参与后续研究,以确认最初的阳性反应并评估感染的自然史。
2003年和2004年的常规检测发现540份献血的西尼罗河病毒RNA呈阳性,其中362份(67%)IgM抗体呈阴性,很可能具有传染性。在这540份阳性献血中,148份(27%)仅通过单个献血检测才能检测到,但这148份中只有15份(10%)IgM抗体呈阴性。流行期间RNA阳性献血的总体频率在2003年为每10000份献血中有1.49份,在2004年为每10000份中有0.44份。2004年,52%的阳性献血来自南加州四个县的献血者。
快速实施核酸扩增检测使得前瞻性地识别出519名西尼罗河病毒RNA呈阳性的献血者,并从红十字会的血液供应中去除了1000多个潜在感染性相关成分。在接受检测血液的受血者中未确认有输血传播感染病例。